Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04695769
Status:
COMPLETED
Last Update Posted:
2022-09-02
First Post:
2020-12-24
Brief Title:
Combined Ribavirin With SofosbuvirVelpatasvirVoxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
Sponsor:
Helwan University
Organization:
Helwan University
Study Overview
Official Title:
The Role of Combined Ribavirin and SofosbuvirVelpatasvirVoxilaprevir in Treatment of Chronic Hepatitis C Non-responders A Randomized Controlled Trial
Status:
COMPLETED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to assess the role of ribavirin as an adjuvant to sofosbuvirvelpatasvirvoxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None